Spatial Learning Impairments in PLB1Triple Knock-in Alzheimer Mice Are Task-specific and Age-dependent
Overview
Authors
Affiliations
We recently generated an advanced mouse model of Alzheimer's disease (AD) by targeted knock-in of single-copy mutated human amyloid precursor-protein (APP) and tau genes, crossed with a non-symptomatic presenilin (PS1A246E) over-expressing mouse line. These PLB1Triple mice presented with age-dependent and AD-relevant phenotypes. Homozygous PLB1Triple mice aged 4-12 months were assessed here in a battery of spatial learning tasks: Exp.1 radial-arm water maze (spatial reference and working memory) Exp.2 open-field water maze (spatial reference memory); Exp.3 home cage observation system with spatial learning (IntelliCage); Exp.4 spontaneous object recognition (SOR; novel object and spatial object shift). A separate test with high-expression transgenic APP mice matching the design of experiment 1 was also performed. Spatial deficits in PLB1Triple mice were confirmed at 12, but not 4 months in both water maze tasks. PSAPP mice, by contrast, presented with severe yet non-progressive spatial learning deficits already at 4 months. During tests of spatial learning in SOR and IntelliCage, PLB1Triple mice neither acquired the location of the water-rewarded corner, nor recognize novel or spatially shifted objects at 4 months, indicating these protocols to be more sensitive than the water maze. Collectively and in line with AD symptomatology, PLB1Triple mice present with a graded and progressive age-dependent loss of spatial memory that can be revealed by the use of a battery of tasks. With the emergence of subtle deficits progressively increasing in severity, PLB1Triple mice may offer a more patho-physiologically relevant model of dementia than aggressive expression models.
Lipp H, Krackow S, Turkes E, Benner S, Endo T, Russig H Front Behav Neurosci. 2024; 17:1270538.
PMID: 38235003 PMC: 10793385. DOI: 10.3389/fnbeh.2023.1270538.
Progressive sleep disturbance in various transgenic mouse models of Alzheimer's disease.
Drew V, Wang C, Kim T Front Aging Neurosci. 2023; 15:1119810.
PMID: 37273656 PMC: 10235623. DOI: 10.3389/fnagi.2023.1119810.
Winslow W, McDonough I, Tallino S, Decker A, Vural A, Velazquez R Front Aging Neurosci. 2021; 13():720214.
PMID: 34483889 PMC: 8414893. DOI: 10.3389/fnagi.2021.720214.
Sutoko S, Masuda A, Kandori A, Sasaguri H, Saito T, Saido T iScience. 2021; 24(3):102198.
PMID: 33733064 PMC: 7937558. DOI: 10.1016/j.isci.2021.102198.
Gene therapy using Aβ variants for amyloid reduction.
Park K, Wood C, Li J, Taylor B, Oh S, Young N Mol Ther. 2021; 29(7):2294-2307.
PMID: 33647457 PMC: 8261072. DOI: 10.1016/j.ymthe.2021.02.026.